EFTA00359717.pdf

From: "James Meiskin" To:' "C Subject: FW: Confidential Date: Wed, 29 Oct 2014 12:15:01 +0000 Attachments: DaCart_Presentation Jul_7_2014.pdf Lesley, I attached the updated deck for JE's review. David Carter would like to meet Jeffrey over the next several weeks if possible, and I think that they would have much in common on many levels, and that Jeffrey would find the meeting to be worthwhile. Please let me know. Thank you. James Dear James, Like I have said in an earlier email. I am looking for an "investing partner" to match (50%/50%) the money Russian Venture Capital plans to invest in USA based Biotechnology. They will provide half of the capital to develop a variety of technologies that are of interest to their country. For their investment they get commercialization rights to the technologies they finance for Russia and the CIS. For us, on the USA side, this is a major source of capital to start a series of companies that have great potential as therapeutic technologies, and we get commercialization rights for the USA, and rest of the world markets. Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital that thinks this is an interesting investment theme, and is willing to consider the idea as something they might want to implement. My belief is that there is more money in NYC, seeking an investment home, then there are "quality investment ideas". I could be wrong, but I have to believe that people running a lot of capital in New York would want to hear new, creative, and GOOD new investment ideas. I think this idea is the kind of idea that is worth a look, and worth serious consideration. I think we are talking $150M over a five year horizon. EFTA00359717 Best, David David W. Caner President—DaCart Capital LLC EFTA00359718